Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
about
Proposed mechanisms of action for prostate cancer vaccines.Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man studyThe Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis.Cancer immunotherapies, their safety and toxicity.Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy.Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14(+) PD-L1(+) phenotype in prostate cancer.Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.Elimination of CD4HLA-G T cells overcomes castration-resistance in prostate cancer therapyQuantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival
P2860
Q35174754-AEB1F7ED-F454-47FB-A7AA-9E174948BCE6Q35592471-50C7531A-0003-42CD-9C77-C54243FD934BQ36771989-E60ED390-C15C-4B2C-B2B8-BC7F0F3BACE7Q37443603-7D5881DC-6379-4077-A348-A5624EE5F8F8Q38099153-F45042F4-3E68-4CC5-8771-D14DD9A87EFBQ38106230-CDB08B90-F1C9-4404-A6AE-5F0CD627FD07Q38133654-812C9959-57DC-40A5-BC8E-4C08D8C57A85Q38760061-B495B97C-6308-4E0D-ACA5-80A3B238216BQ38839675-6CA2FA22-49D9-4842-9C34-7AA8B3CE56E6Q39155959-73C7B7F2-3878-4823-81B1-771ABF1F0E00Q42476576-509C2A4B-D175-400A-B25D-F3FB65676C06Q47759603-2C21D284-5BDE-4391-9160-A608FC514454Q57293807-0CC8D828-6A8C-4369-AF3B-9E16E986DEE9Q58282086-1C56E702-BF27-4F27-96B2-C390266378CB
P2860
Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
@en
type
label
Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
@en
prefLabel
Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
@en
P2093
P2860
P356
P1476
Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
@en
P2093
J Brantley Thrasher
Jeffrey M Holzbeierlein
Peter Van Veldhuizen
P2860
P2888
P304
P356
10.1038/NRUROL.2012.106
P407
P577
2012-05-29T00:00:00Z
P6179
1035759038